Coordinated increase of γ-secretase reaction products in the plasma of some female Japanese sporadic Alzheimer's disease patients: quantitative analysis of p3-Alcα with a new ELISA system

Background Aggregatable amyloid β-peptide (Aβ) and non-aggregatable p3-Alcα are metabolic products of the γ-secretase cleavage of amyloid β-protein precursor (APP) and Alcadeinα (Alcα), respectively. Familial AD (FAD) -linked mutations in the presenilin 1 or 2 (PS1 or PS2) component of γ-secretase c...

Full description

Saved in:

Bibliographic Details
Published in	Molecular neurodegeneration Vol. 6; no. 1; p. 76
Main Authors	Konno, Tomoko, Hata, Saori, Hamada, Yukiko, Horikoshi-Sakuraba, Yuko, Nakaya, Tadashi, Saito, Yuhki, Yamamoto, Tohru, Yamamoto, Takayuki, Maeda, Masahiro, Ikeuchi, Takeshi, Gandy, Sam, Akatsu, Hiroyasu, Suzuki, Toshiharu
Format	Journal Article
Language	English
Published	London BioMed Central 08.11.2011 BioMed Central Ltd BMC
Subjects	Aged Aged, 80 and over Alzheimer Disease - blood Amyloid beta-Peptides - blood Amyloid beta-Protein Precursor - metabolism Amyloid Precursor Protein Secretases - metabolism Animals Asian Continental Ancestry Group Biomedical and Life Sciences Biomedicine Cohort Studies Enzyme-Linked Immunosorbent Assay - methods Female Frontotemporal Lobar Degeneration - blood Humans Male Middle Aged Molecular Medicine Neurology Neurosciences Plasma - metabolism Research Article Japanese Cohort Healthy Human Serum Chronic Traumatic Encephalopathy Elderly Normal Control Closed Diamond
Online Access	Get full text
ISSN	1750-1326 1750-1326
DOI	10.1186/1750-1326-6-76

Cover

Abstract	Background Aggregatable amyloid β-peptide (Aβ) and non-aggregatable p3-Alcα are metabolic products of the γ-secretase cleavage of amyloid β-protein precursor (APP) and Alcadeinα (Alcα), respectively. Familial AD (FAD) -linked mutations in the presenilin 1 or 2 (PS1 or PS2) component of γ-secretase can cause alternative intramembranous processing of APP and Alcα, leading to a coordinated generation of variants of both Aβ and p3-Alcα. Variant Alcα peptides have been observed in the cerebrospinal fluid (CSF) of patients with mild cognitive impairment and sporadic Alzheimer's disease (AD). Since, like APP, Alcα is largely expressed in brain, one might predict that alternative processing of Alcα would be reflected in body fluids of some AD patients. These patients with misprocessing of multiple γ-secretase substrates might define an endophenotype of p3-Alcα, in whom AD is due either to dysfunction of γ-secretase or to a disorder of the clearance of hydrophobic peptides such as those derived from transmembrane domains. Results We developed a simple procedure for extraction of p3-Alcα from plasma and for analyzing this extract in a sensitive, p3-Alcα-specific sandwich enzyme-linked immunosorbent assay (ELISA) system. Plasma p3-Alcα levels and Aβ40 levels were examined in sporadic AD subjects from two independent Japanese cohorts. In some of these patients, levels of plasma p3-Alcα were significantly higher, and were accompanied by parallel changes in Aβ40 levels. This AD-related difference was more marked in female subjects, but this phenomenon was not observed in subjects with frontotemporal lobar degeneration (FTLD). Conclusion Reagents and procedures have been established that enable extraction of p3-Alcα from plasma and for quantification of plasma p3-Alcα levels by ELISA. Some populations of AD subjects apparently show increased levels of both p3-Alcα and Aβ40. Quantification of p3-Alcα level may be useful as a readily accessible biomarker for a population of sporadic AD patients in which disease pathogenesis is associated with either dysfunction of γ-secretase or with a disorder of the clearance of transmembrane domain-derived peptides.
AbstractList	Background Aggregatable amyloid β-peptide (Aβ) and non-aggregatable p3-Alcα are metabolic products of the γ-secretase cleavage of amyloid β-protein precursor (APP) and Alcadeinα (Alcα), respectively. Familial AD (FAD) -linked mutations in the presenilin 1 or 2 (PS1 or PS2) component of γ-secretase can cause alternative intramembranous processing of APP and Alcα, leading to a coordinated generation of variants of both Aβ and p3-Alcα. Variant Alcα peptides have been observed in the cerebrospinal fluid (CSF) of patients with mild cognitive impairment and sporadic Alzheimer's disease (AD). Since, like APP, Alcα is largely expressed in brain, one might predict that alternative processing of Alcα would be reflected in body fluids of some AD patients. These patients with misprocessing of multiple γ-secretase substrates might define an endophenotype of p3-Alcα, in whom AD is due either to dysfunction of γ-secretase or to a disorder of the clearance of hydrophobic peptides such as those derived from transmembrane domains. Results We developed a simple procedure for extraction of p3-Alcα from plasma and for analyzing this extract in a sensitive, p3-Alcα-specific sandwich enzyme-linked immunosorbent assay (ELISA) system. Plasma p3-Alcα levels and Aβ40 levels were examined in sporadic AD subjects from two independent Japanese cohorts. In some of these patients, levels of plasma p3-Alcα were significantly higher, and were accompanied by parallel changes in Aβ40 levels. This AD-related difference was more marked in female subjects, but this phenomenon was not observed in subjects with frontotemporal lobar degeneration (FTLD). Conclusion Reagents and procedures have been established that enable extraction of p3-Alcα from plasma and for quantification of plasma p3-Alcα levels by ELISA. Some populations of AD subjects apparently show increased levels of both p3-Alcα and Aβ40. Quantification of p3-Alcα level may be useful as a readily accessible biomarker for a population of sporadic AD patients in which disease pathogenesis is associated with either dysfunction of γ-secretase or with a disorder of the clearance of transmembrane domain-derived peptides. Abstract Background Aggregatable amyloid β-peptide (Aβ) and non-aggregatable p3-Alcα are metabolic products of the γ-secretase cleavage of amyloid β-protein precursor (APP) and Alcadeinα (Alcα), respectively. Familial AD (FAD) -linked mutations in the presenilin 1 or 2 (PS1 or PS2) component of γ-secretase can cause alternative intramembranous processing of APP and Alcα, leading to a coordinated generation of variants of both Aβ and p3-Alcα. Variant Alcα peptides have been observed in the cerebrospinal fluid (CSF) of patients with mild cognitive impairment and sporadic Alzheimer's disease (AD). Since, like APP, Alcα is largely expressed in brain, one might predict that alternative processing of Alcα would be reflected in body fluids of some AD patients. These patients with misprocessing of multiple γ-secretase substrates might define an endophenotype of p3-Alcα, in whom AD is due either to dysfunction of γ-secretase or to a disorder of the clearance of hydrophobic peptides such as those derived from transmembrane domains. Results We developed a simple procedure for extraction of p3-Alcα from plasma and for analyzing this extract in a sensitive, p3-Alcα-specific sandwich enzyme-linked immunosorbent assay (ELISA) system. Plasma p3-Alcα levels and Aβ40 levels were examined in sporadic AD subjects from two independent Japanese cohorts. In some of these patients, levels of plasma p3-Alcα were significantly higher, and were accompanied by parallel changes in Aβ40 levels. This AD-related difference was more marked in female subjects, but this phenomenon was not observed in subjects with frontotemporal lobar degeneration (FTLD). Conclusion Reagents and procedures have been established that enable extraction of p3-Alcα from plasma and for quantification of plasma p3-Alcα levels by ELISA. Some populations of AD subjects apparently show increased levels of both p3-Alcα and Aβ40. Quantification of p3-Alcα level may be useful as a readily accessible biomarker for a population of sporadic AD patients in which disease pathogenesis is associated with either dysfunction of γ-secretase or with a disorder of the clearance of transmembrane domain-derived peptides. BACKGROUND: Aggregatable amyloid β-peptide (Aβ) and non-aggregatable p3-Alcα are metabolic products of the γ-secretase cleavage of amyloid β-protein precursor (APP) and Alcadeinα (Alcα), respectively. Familial AD (FAD) -linked mutations in the presenilin 1 or 2 (PS1 or PS2) component of γ-secretase can cause alternative intramembranous processing of APP and Alcα, leading to a coordinated generation of variants of both Aβ and p3-Alcα. Variant Alcα peptides have been observed in the cerebrospinal fluid (CSF) of patients with mild cognitive impairment and sporadic Alzheimer's disease (AD). Since, like APP, Alcα is largely expressed in brain, one might predict that alternative processing of Alcα would be reflected in body fluids of some AD patients. These patients with misprocessing of multiple γ-secretase substrates might define an endophenotype of p3-Alcα, in whom AD is due either to dysfunction of γ-secretase or to a disorder of the clearance of hydrophobic peptides such as those derived from transmembrane domains. RESULTS: We developed a simple procedure for extraction of p3-Alcα from plasma and for analyzing this extract in a sensitive, p3-Alcα-specific sandwich enzyme-linked immunosorbent assay (ELISA) system. Plasma p3-Alcα levels and Aβ40 levels were examined in sporadic AD subjects from two independent Japanese cohorts. In some of these patients, levels of plasma p3-Alcα were significantly higher, and were accompanied by parallel changes in Aβ40 levels. This AD-related difference was more marked in female subjects, but this phenomenon was not observed in subjects with frontotemporal lobar degeneration (FTLD). CONCLUSION: Reagents and procedures have been established that enable extraction of p3-Alcα from plasma and for quantification of plasma p3-Alcα levels by ELISA. Some populations of AD subjects apparently show increased levels of both p3-Alcα and Aβ40. Quantification of p3-Alcα level may be useful as a readily accessible biomarker for a population of sporadic AD patients in which disease pathogenesis is associated with either dysfunction of γ-secretase or with a disorder of the clearance of transmembrane domain-derived peptides. Aggregatable amyloid β-peptide (Aβ) and non-aggregatable p3-Alcα are metabolic products of the γ-secretase cleavage of amyloid β-protein precursor (APP) and Alcadeinα (Alcα), respectively. Familial AD (FAD) -linked mutations in the presenilin 1 or 2 (PS1 or PS2) component of γ-secretase can cause alternative intramembranous processing of APP and Alcα, leading to a coordinated generation of variants of both Aβ and p3-Alcα. Variant Alcα peptides have been observed in the cerebrospinal fluid (CSF) of patients with mild cognitive impairment and sporadic Alzheimer's disease (AD). Since, like APP, Alcα is largely expressed in brain, one might predict that alternative processing of Alcα would be reflected in body fluids of some AD patients. These patients with misprocessing of multiple γ-secretase substrates might define an endophenotype of p3-Alcα, in whom AD is due either to dysfunction of γ-secretase or to a disorder of the clearance of hydrophobic peptides such as those derived from transmembrane domains. We developed a simple procedure for extraction of p3-Alcα from plasma and for analyzing this extract in a sensitive, p3-Alcα-specific sandwich enzyme-linked immunosorbent assay (ELISA) system. Plasma p3-Alcα levels and Aβ40 levels were examined in sporadic AD subjects from two independent Japanese cohorts. In some of these patients, levels of plasma p3-Alcα were significantly higher, and were accompanied by parallel changes in Aβ40 levels. This AD-related difference was more marked in female subjects, but this phenomenon was not observed in subjects with frontotemporal lobar degeneration (FTLD). Reagents and procedures have been established that enable extraction of p3-Alcα from plasma and for quantification of plasma p3-Alcα levels by ELISA. Some populations of AD subjects apparently show increased levels of both p3-Alcα and Aβ40. Quantification of p3-Alcα level may be useful as a readily accessible biomarker for a population of sporadic AD patients in which disease pathogenesis is associated with either dysfunction of γ-secretase or with a disorder of the clearance of transmembrane domain-derived peptides. Aggregatable amyloid β-peptide (Aβ) and non-aggregatable p3-Alcα are metabolic products of the γ-secretase cleavage of amyloid β-protein precursor (APP) and Alcadeinα (Alcα), respectively. Familial AD (FAD) -linked mutations in the presenilin 1 or 2 (PS1 or PS2) component of γ-secretase can cause alternative intramembranous processing of APP and Alcα, leading to a coordinated generation of variants of both Aβ and p3-Alcα. Variant Alcα peptides have been observed in the cerebrospinal fluid (CSF) of patients with mild cognitive impairment and sporadic Alzheimer's disease (AD). Since, like APP, Alcα is largely expressed in brain, one might predict that alternative processing of Alcα would be reflected in body fluids of some AD patients. These patients with misprocessing of multiple γ-secretase substrates might define an endophenotype of p3-Alcα, in whom AD is due either to dysfunction of γ-secretase or to a disorder of the clearance of hydrophobic peptides such as those derived from transmembrane domains.BACKGROUNDAggregatable amyloid β-peptide (Aβ) and non-aggregatable p3-Alcα are metabolic products of the γ-secretase cleavage of amyloid β-protein precursor (APP) and Alcadeinα (Alcα), respectively. Familial AD (FAD) -linked mutations in the presenilin 1 or 2 (PS1 or PS2) component of γ-secretase can cause alternative intramembranous processing of APP and Alcα, leading to a coordinated generation of variants of both Aβ and p3-Alcα. Variant Alcα peptides have been observed in the cerebrospinal fluid (CSF) of patients with mild cognitive impairment and sporadic Alzheimer's disease (AD). Since, like APP, Alcα is largely expressed in brain, one might predict that alternative processing of Alcα would be reflected in body fluids of some AD patients. These patients with misprocessing of multiple γ-secretase substrates might define an endophenotype of p3-Alcα, in whom AD is due either to dysfunction of γ-secretase or to a disorder of the clearance of hydrophobic peptides such as those derived from transmembrane domains.We developed a simple procedure for extraction of p3-Alcα from plasma and for analyzing this extract in a sensitive, p3-Alcα-specific sandwich enzyme-linked immunosorbent assay (ELISA) system. Plasma p3-Alcα levels and Aβ40 levels were examined in sporadic AD subjects from two independent Japanese cohorts. In some of these patients, levels of plasma p3-Alcα were significantly higher, and were accompanied by parallel changes in Aβ40 levels. This AD-related difference was more marked in female subjects, but this phenomenon was not observed in subjects with frontotemporal lobar degeneration (FTLD).RESULTSWe developed a simple procedure for extraction of p3-Alcα from plasma and for analyzing this extract in a sensitive, p3-Alcα-specific sandwich enzyme-linked immunosorbent assay (ELISA) system. Plasma p3-Alcα levels and Aβ40 levels were examined in sporadic AD subjects from two independent Japanese cohorts. In some of these patients, levels of plasma p3-Alcα were significantly higher, and were accompanied by parallel changes in Aβ40 levels. This AD-related difference was more marked in female subjects, but this phenomenon was not observed in subjects with frontotemporal lobar degeneration (FTLD).Reagents and procedures have been established that enable extraction of p3-Alcα from plasma and for quantification of plasma p3-Alcα levels by ELISA. Some populations of AD subjects apparently show increased levels of both p3-Alcα and Aβ40. Quantification of p3-Alcα level may be useful as a readily accessible biomarker for a population of sporadic AD patients in which disease pathogenesis is associated with either dysfunction of γ-secretase or with a disorder of the clearance of transmembrane domain-derived peptides.CONCLUSIONReagents and procedures have been established that enable extraction of p3-Alcα from plasma and for quantification of plasma p3-Alcα levels by ELISA. Some populations of AD subjects apparently show increased levels of both p3-Alcα and Aβ40. Quantification of p3-Alcα level may be useful as a readily accessible biomarker for a population of sporadic AD patients in which disease pathogenesis is associated with either dysfunction of γ-secretase or with a disorder of the clearance of transmembrane domain-derived peptides.
ArticleNumber	76
Author	Yamamoto, Takayuki Nakaya, Tadashi Konno, Tomoko Yamamoto, Tohru Horikoshi-Sakuraba, Yuko Maeda, Masahiro Saito, Yuhki Hamada, Yukiko Gandy, Sam Hata, Saori Suzuki, Toshiharu Akatsu, Hiroyasu Ikeuchi, Takeshi
AuthorAffiliation	4 Department of Molecular Neuroscience, Brain Research Institute, Niigata University, Niigata 951-8585, Japan 7 James J. Peters Veterans Administration Medical Center, NY 10468, USA 2 Immuno-Biological Laboratories Co., Ltd. (IBL), Fujioka 375-0005, Japan 5 Department of Neurology, Mount Sinai School of Medicine, Alzheimer's Disease Research Center, New York, NY 10029, USA 3 Choju Medical Institute, Fukushimura Hospital, Toyohashi 441-8124, Japan 6 Department of Psychiatry, Mount Sinai School of Medicine, Alzheimer's Disease Research Center, New York, NY 10029, USA 1 Laboratory of Neuroscience, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo 060-0812, Japan
AuthorAffiliation_xml	– name: 3 Choju Medical Institute, Fukushimura Hospital, Toyohashi 441-8124, Japan – name: 4 Department of Molecular Neuroscience, Brain Research Institute, Niigata University, Niigata 951-8585, Japan – name: 6 Department of Psychiatry, Mount Sinai School of Medicine, Alzheimer's Disease Research Center, New York, NY 10029, USA – name: 5 Department of Neurology, Mount Sinai School of Medicine, Alzheimer's Disease Research Center, New York, NY 10029, USA – name: 2 Immuno-Biological Laboratories Co., Ltd. (IBL), Fujioka 375-0005, Japan – name: 1 Laboratory of Neuroscience, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo 060-0812, Japan – name: 7 James J. Peters Veterans Administration Medical Center, NY 10468, USA
Author_xml	– sequence: 1 givenname: Tomoko surname: Konno fullname: Konno, Tomoko organization: Laboratory of Neuroscience, Graduate School of Pharmaceutical Sciences, Hokkaido University – sequence: 2 givenname: Saori surname: Hata fullname: Hata, Saori organization: Laboratory of Neuroscience, Graduate School of Pharmaceutical Sciences, Hokkaido University – sequence: 3 givenname: Yukiko surname: Hamada fullname: Hamada, Yukiko organization: Immuno-Biological Laboratories Co., Ltd. (IBL) – sequence: 4 givenname: Yuko surname: Horikoshi-Sakuraba fullname: Horikoshi-Sakuraba, Yuko organization: Immuno-Biological Laboratories Co., Ltd. (IBL) – sequence: 5 givenname: Tadashi surname: Nakaya fullname: Nakaya, Tadashi organization: Laboratory of Neuroscience, Graduate School of Pharmaceutical Sciences, Hokkaido University – sequence: 6 givenname: Yuhki surname: Saito fullname: Saito, Yuhki organization: Laboratory of Neuroscience, Graduate School of Pharmaceutical Sciences, Hokkaido University – sequence: 7 givenname: Tohru surname: Yamamoto fullname: Yamamoto, Tohru organization: Laboratory of Neuroscience, Graduate School of Pharmaceutical Sciences, Hokkaido University – sequence: 8 givenname: Takayuki surname: Yamamoto fullname: Yamamoto, Takayuki organization: Choju Medical Institute, Fukushimura Hospital – sequence: 9 givenname: Masahiro surname: Maeda fullname: Maeda, Masahiro organization: Immuno-Biological Laboratories Co., Ltd. (IBL) – sequence: 10 givenname: Takeshi surname: Ikeuchi fullname: Ikeuchi, Takeshi organization: Department of Molecular Neuroscience, Brain Research Institute, Niigata University – sequence: 11 givenname: Sam surname: Gandy fullname: Gandy, Sam organization: Department of Neurology, Mount Sinai School of Medicine, Alzheimer's Disease Research Center, Department of Psychiatry, Mount Sinai School of Medicine, Alzheimer's Disease Research Center, James J. Peters Veterans Administration Medical Center – sequence: 12 givenname: Hiroyasu surname: Akatsu fullname: Akatsu, Hiroyasu organization: Choju Medical Institute, Fukushimura Hospital – sequence: 13 givenname: Toshiharu surname: Suzuki fullname: Suzuki, Toshiharu email: tsuzuki@pharm.hokudai.ac.jp organization: Laboratory of Neuroscience, Graduate School of Pharmaceutical Sciences, Hokkaido University
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/22067061$$D View this record in MEDLINE/PubMed
BookMark	eNp1ks2O0zAUhSM0iPmBLUvk3awy4_w6YYFUVQMUVWIBrK0b-6Z1ldgZ251R560Qa15hngmnHaopqKvkXp_z3Zv4nEcn2miMorcJvUqSqrxOWEHjJEvLuIxZ-SI62zdOnr2fRufOrSjNGaXFq-g0TWnJaJmcRb-nxlipNHiURGlhERwS05LHX7HDUPqxDl3hldFksEauhXdBSvwSydCB62HUO9MjabGHDskXGEBj8LnBWJBKkEn3sETVo710RCq3HTKAV6i9e09u16C98qG-QwIauo1TboQOWTzpxONPcq_8kgDReE9u5rNvE-I2zmP_OnrZQufwzdPzIvrx8eb79HM8__ppNp3M46aomY9ZXTCUtSxTwbBhVSMYa4o2ZbRqoIG2lm0Fsi0k0LaqWJEJqLCCKs2TJi2xzC6i2Y4rDaz4YFUPdsMNKL5tGLvgYL0SHfIyEKAtCpBJkmMr6rxldZLXKVayLJoisD7sWMO66VGK8AssdAfQwxOtlnxh7niW5qwqRsBkB2iUOQI4PBGm52MU-BgFXnI2ftDl0xLW3K7Red4rJ7Drwr2ZteN1UtEszygNynfP192P-RuhILjaCYQ1zlls95IkTAwZ_X92_o9BbO_ejNuq7rjtemdzga8XaPnKrG0Iizvm-APXCP_G
CitedBy_id	crossref_primary_10_1186_1750_1326_7_16 crossref_primary_10_3233_JAD_200900 crossref_primary_10_3390_jcm9113452 crossref_primary_10_1038_s41598_024_69400_9 crossref_primary_10_1074_jbc_M114_599852 crossref_primary_10_1074_jbc_RA119_012386 crossref_primary_10_1248_yakushi_15_00189 crossref_primary_10_1016_j_trci_2019_09_015 crossref_primary_10_1002_psp4_12211 crossref_primary_10_1091_mbc_e17_05_0301
Cites_doi	10.1074/jbc.M109.057497 10.1038/ng.801 10.1126/science.1197623 10.1002/emmm.200900026 10.1212/WNL.51.6.1546 10.1038/nrm2101 10.1001/jama.2010.1995 10.1212/WNL.0b013e3181b78448 10.1016/S0306-4522(98)00561-2 10.1016/S1474-4422(10)70325-2 10.1016/S0304-3940(00)01675-X 10.1038/sj.emboj.7601609 10.1056/NEJMp1007051 10.2174/157488408784293723 10.1038/sj.embor.7400897 10.1038/nm1782 10.1074/jbc.M401925200 10.1385/JMN:20:3:287 10.3233/JAD-2010-100141 10.1016/S0896-6273(00)80230-5 10.1001/archneur.64.3.354 10.1089/neu.2008.0843 10.1001/jama.1997.03550020068040 10.1002/ana.22343 10.1038/375754a0 10.1523/JNEUROSCI.23-26-08867.2003 10.1007/s00401-011-0808-0 10.1038/nm0498-447 10.1046/j.0022-3042.2001.00690.x 10.1074/jbc.M306024200 10.1074/jbc.R800010200 10.1159/000282279
ContentType	Journal Article
Copyright	Konno et al; licensee BioMed Central Ltd. 2011 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Copyright ©2011 Konno et al; licensee BioMed Central Ltd. 2011 Konno et al; licensee BioMed Central Ltd.
Copyright_xml	– notice: Konno et al; licensee BioMed Central Ltd. 2011 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. – notice: Copyright ©2011 Konno et al; licensee BioMed Central Ltd. 2011 Konno et al; licensee BioMed Central Ltd.
CorporateAuthor	the Japanese Alzheimer's Disease Neuroimaging Initiative Japanese Alzheimer's Disease Neuroimaging Initiative
CorporateAuthor_xml	– name: the Japanese Alzheimer's Disease Neuroimaging Initiative – name: Japanese Alzheimer's Disease Neuroimaging Initiative
DBID	C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA
DOI	10.1186/1750-1326-6-76
DatabaseName	Springer Nature OA Free Journals (Selected full-text) CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE MEDLINE - Academic
Database_xml	– sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Anatomy & Physiology
EISSN	1750-1326
EndPage	76
ExternalDocumentID	oai_doaj_org_article_6f88af55ad114efc94f791492e8d65b5 PMC3247855 oai_biomedcentral_com_1750_1326_6_76 22067061 10_1186_1750_1326_6_76
Genre	Evaluation Studies Research Support, Non-U.S. Gov't Journal Article
GroupedDBID	--- 0R~ 123 29M 2VQ 2WC 4.4 53G 5VS 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML ABDBF ABIVO ABUWG ACGFO ACGFS ACIHN ACMJI ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHSBF AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CS3 DIK DU5 E3Z EBD EBLON EBS EJD ESX F5P FYUFA GROUPED_DOAJ GX1 H13 HH5 HMCUK HYE IAO IHR INH INR IPNFZ IPY ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ RIG RNS ROL RPM RSV SBL SOJ TR2 TUS UKHRP WOQ WOW ~8M AAYXX ALIPV CITATION CGR CUY CVF ECM EIF NPM 7X8 -A0 3V. ABVAZ ACRMQ ADINQ AFGXO AFNRJ C24 5PM
ID	FETCH-LOGICAL-b597t-7957ed9d62c7eb78bc77b5f2708babaf9df8adf5da0f88753ca8e8a8241b26e63
IEDL.DBID	M48
ISSN	1750-1326
IngestDate	Wed Aug 27 00:36:16 EDT 2025 Thu Aug 21 18:33:56 EDT 2025 Wed May 22 07:16:12 EDT 2024 Thu Sep 04 23:28:44 EDT 2025 Thu Apr 03 07:08:25 EDT 2025 Tue Jul 01 01:59:00 EDT 2025 Thu Apr 24 23:02:31 EDT 2025 Sat Sep 06 07:29:29 EDT 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	1
Keywords	Japanese Cohort Healthy Human Serum Chronic Traumatic Encephalopathy Elderly Normal Control Closed Diamond
Language	English
License	This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-b597t-7957ed9d62c7eb78bc77b5f2708babaf9df8adf5da0f88753ca8e8a8241b26e63
Notes	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Undefined-1 ObjectType-Feature-3 content type line 23
OpenAccessLink	http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/1750-1326-6-76
PMID	22067061
PQID	918034300
PQPubID	23479
PageCount	1
ParticipantIDs	doaj_primary_oai_doaj_org_article_6f88af55ad114efc94f791492e8d65b5 pubmedcentral_primary_oai_pubmedcentral_nih_gov_3247855 biomedcentral_primary_oai_biomedcentral_com_1750_1326_6_76 proquest_miscellaneous_918034300 pubmed_primary_22067061 crossref_primary_10_1186_1750_1326_6_76 crossref_citationtrail_10_1186_1750_1326_6_76 springer_journals_10_1186_1750_1326_6_76
ProviderPackageCode	CITATION AAYXX
PublicationCentury	2000
PublicationDate	2011-11-08
PublicationDateYYYYMMDD	2011-11-08
PublicationDate_xml	– month: 11 year: 2011 text: 2011-11-08 day: 08
PublicationDecade	2010
PublicationPlace	London
PublicationPlace_xml	– name: London – name: England
PublicationTitle	Molecular neurodegeneration
PublicationTitleAbbrev	Mol Neurodegeneration
PublicationTitleAlternate	Mol Neurodegener
PublicationYear	2011
Publisher	BioMed Central BioMed Central Ltd BMC
Publisher_xml	– name: BioMed Central – name: BioMed Central Ltd – name: BMC
References	Y Araki (233_CR1) 2003; 278 S Hata (233_CR4) 2009; 284 H Zheng (233_CR23) 2002; 80 Y Araki (233_CR3) 2007; 26 R Sherrιngton (233_CR8) 1995; 375 PB Verghese (233_CR25) 2011; 10 GM Shankar (233_CR11) 2008; 14 B De Strooper (233_CR6) 2007; 8 JC Lambert (233_CR14) 2009; 73 ST DeKosky (233_CR29) 2010; 363 LC Nord (233_CR24) 2010; 7 K Yasojima (233_CR26) 2001; 297 DS Yang (233_CR19) 1999; 90 AC Naj (233_CR21) 2011; 43 C Haass (233_CR10) 2007; 8 JP Melchor (233_CR31) 2003; 20 KG Mawuenyega (233_CR18) 2010; 330 VE Johnson (233_CR28) 2009; 26 H Xu (233_CR22) 1998; 4 BD Jordan (233_CR27) 1997; 278 K Yanagida (233_CR17) 2009; 1 NR Graff-Radford (233_CR15) 2007; 64 K Yaffe (233_CR16) 2011; 305 H Steiner (233_CR7) 2008; 283 DR Borchelt (233_CR9) 1996; 17 LM Shaw (233_CR12) 2011; 121 Y Araki (233_CR2) 2004; 279 MJ Sharman (233_CR20) 2010; 21 JP Melchor (233_CR30) 2003; 23 S Hata (233_CR5) 2011; 69 D Neary (233_CR32) 1998; 51 SV Frankfort (233_CR13) 2008; 3 17332754 - EMBO J. 2007 Mar 21;26(6):1475-86 14523088 - J Neurosci. 2003 Oct 1;23(26):8867-71 17353377 - Arch Neurol. 2007 Mar;64(3):354-62 14501010 - J Mol Neurosci. 2003;20(3):287-9 18650432 - J Biol Chem. 2008 Oct 31;283(44):29627-31 12972431 - J Biol Chem. 2003 Dec 5;278(49):49448-58 21148344 - Science. 2010 Dec 24;330(6012):1774 20523023 - Neurodegener Dis. 2010;7(6):349-64 20879875 - N Engl J Med. 2010 Sep 30;363(14):1293-6 21311900 - Acta Neuropathol. 2011 May;121(5):597-609 19326964 - J Neurotrauma. 2009 Aug;26(8):1197-202 18700307 - Curr Clin Pharmacol. 2008 May;3(2):123-31 10338292 - Neuroscience. 1999;90(4):1217-26 21681798 - Ann Neurol. 2011 Jun;69(6):1026-31 21460841 - Nat Genet. 2011 May;43(5):436-41 7596406 - Nature. 1995 Jun 29;375(6534):754-60 8938131 - Neuron. 1996 Nov;17(5):1005-13 9855500 - Neurology. 1998 Dec;51(6):1546-54 11796757 - J Neurochem. 2002 Jan;80(1):191-6 15037614 - J Biol Chem. 2004 Jun 4;279(23):24343-54 9546791 - Nat Med. 1998 Apr;4(4):447-51 19864413 - J Biol Chem. 2009 Dec 25;284(52):36024-33 9214529 - JAMA. 1997 Jul 9;278(2):136-40 19752451 - Neurology. 2009 Sep 15;73(11):847-53 20555142 - J Alzheimers Dis. 2010;21(2):403-9 20049724 - EMBO Mol Med. 2009 Jul;1(4):223-35 17245412 - Nat Rev Mol Cell Biol. 2007 Feb;8(2):101-12 18568035 - Nat Med. 2008 Aug;14(8):837-42 21245181 - JAMA. 2011 Jan 19;305(3):261-6 21349439 - Lancet Neurol. 2011 Mar;10(3):241-52 11121879 - Neurosci Lett. 2001 Jan 12;297(2):97-100 17268505 - EMBO Rep. 2007 Feb;8(2):141-6
References_xml	– volume: 284 start-page: 36024 year: 2009 ident: 233_CR4 publication-title: J Biol Chem doi: 10.1074/jbc.M109.057497 – volume: 43 start-page: 436 year: 2011 ident: 233_CR21 publication-title: Nat Genet doi: 10.1038/ng.801 – volume: 330 start-page: 1774 year: 2010 ident: 233_CR18 publication-title: Science doi: 10.1126/science.1197623 – volume: 1 start-page: 223 year: 2009 ident: 233_CR17 publication-title: EMBO Mol Med doi: 10.1002/emmm.200900026 – volume: 51 start-page: 1546 year: 1998 ident: 233_CR32 publication-title: Neurology doi: 10.1212/WNL.51.6.1546 – volume: 8 start-page: 101 year: 2007 ident: 233_CR10 publication-title: Nat Rev Moll Cell Biol doi: 10.1038/nrm2101 – volume: 305 start-page: 261 year: 2011 ident: 233_CR16 publication-title: JAMA doi: 10.1001/jama.2010.1995 – volume: 73 start-page: 847 year: 2009 ident: 233_CR14 publication-title: Exp Neurol doi: 10.1212/WNL.0b013e3181b78448 – volume: 90 start-page: 1217 year: 1999 ident: 233_CR19 publication-title: Neuroscience doi: 10.1016/S0306-4522(98)00561-2 – volume: 10 start-page: 241 year: 2011 ident: 233_CR25 publication-title: Lancet Neurol doi: 10.1016/S1474-4422(10)70325-2 – volume: 297 start-page: 97 year: 2001 ident: 233_CR26 publication-title: Neurosci Lett doi: 10.1016/S0304-3940(00)01675-X – volume: 26 start-page: 1475 year: 2007 ident: 233_CR3 publication-title: EMBO J doi: 10.1038/sj.emboj.7601609 – volume: 363 start-page: 1293 year: 2010 ident: 233_CR29 publication-title: N Engl J Med doi: 10.1056/NEJMp1007051 – volume: 3 start-page: 123 year: 2008 ident: 233_CR13 publication-title: Curr Clin Pharmacol doi: 10.2174/157488408784293723 – volume: 8 start-page: 141 year: 2007 ident: 233_CR6 publication-title: EMBO Rep doi: 10.1038/sj.embor.7400897 – volume: 14 start-page: 837 year: 2008 ident: 233_CR11 publication-title: Nat Med doi: 10.1038/nm1782 – volume: 279 start-page: 24343 year: 2004 ident: 233_CR2 publication-title: J Biol Chem doi: 10.1074/jbc.M401925200 – volume: 20 start-page: 287 year: 2003 ident: 233_CR31 publication-title: J Mol Neurosci doi: 10.1385/JMN:20:3:287 – volume: 21 start-page: 403 year: 2010 ident: 233_CR20 publication-title: J Alzheimers Dis doi: 10.3233/JAD-2010-100141 – volume: 17 start-page: 1005 year: 1996 ident: 233_CR9 publication-title: Neuron doi: 10.1016/S0896-6273(00)80230-5 – volume: 64 start-page: 354 year: 2007 ident: 233_CR15 publication-title: Arch Neurol doi: 10.1001/archneur.64.3.354 – volume: 26 start-page: 1197 year: 2009 ident: 233_CR28 publication-title: J Neurotrauma doi: 10.1089/neu.2008.0843 – volume: 278 start-page: 136 year: 1997 ident: 233_CR27 publication-title: JAMA doi: 10.1001/jama.1997.03550020068040 – volume: 69 start-page: 1026 year: 2011 ident: 233_CR5 publication-title: Ann Neurol doi: 10.1002/ana.22343 – volume: 375 start-page: 754 year: 1995 ident: 233_CR8 publication-title: Nature doi: 10.1038/375754a0 – volume: 23 start-page: 8867 year: 2003 ident: 233_CR30 publication-title: J Neurosci doi: 10.1523/JNEUROSCI.23-26-08867.2003 – volume: 121 start-page: 597 year: 2011 ident: 233_CR12 publication-title: Acta Neuropathol doi: 10.1007/s00401-011-0808-0 – volume: 4 start-page: 447 year: 1998 ident: 233_CR22 publication-title: Nat Med doi: 10.1038/nm0498-447 – volume: 80 start-page: 191 year: 2002 ident: 233_CR23 publication-title: J Neurochem doi: 10.1046/j.0022-3042.2001.00690.x – volume: 278 start-page: 49448 year: 2003 ident: 233_CR1 publication-title: J Biol Chem doi: 10.1074/jbc.M306024200 – volume: 283 start-page: 29627 year: 2008 ident: 233_CR7 publication-title: J Biol Chem doi: 10.1074/jbc.R800010200 – volume: 7 start-page: 349 year: 2010 ident: 233_CR24 publication-title: Neurodegener Dis doi: 10.1159/000282279 – reference: 18700307 - Curr Clin Pharmacol. 2008 May;3(2):123-31 – reference: 10338292 - Neuroscience. 1999;90(4):1217-26 – reference: 21681798 - Ann Neurol. 2011 Jun;69(6):1026-31 – reference: 17332754 - EMBO J. 2007 Mar 21;26(6):1475-86 – reference: 20049724 - EMBO Mol Med. 2009 Jul;1(4):223-35 – reference: 14501010 - J Mol Neurosci. 2003;20(3):287-9 – reference: 21349439 - Lancet Neurol. 2011 Mar;10(3):241-52 – reference: 11796757 - J Neurochem. 2002 Jan;80(1):191-6 – reference: 21245181 - JAMA. 2011 Jan 19;305(3):261-6 – reference: 8938131 - Neuron. 1996 Nov;17(5):1005-13 – reference: 9546791 - Nat Med. 1998 Apr;4(4):447-51 – reference: 12972431 - J Biol Chem. 2003 Dec 5;278(49):49448-58 – reference: 14523088 - J Neurosci. 2003 Oct 1;23(26):8867-71 – reference: 20555142 - J Alzheimers Dis. 2010;21(2):403-9 – reference: 9214529 - JAMA. 1997 Jul 9;278(2):136-40 – reference: 21311900 - Acta Neuropathol. 2011 May;121(5):597-609 – reference: 15037614 - J Biol Chem. 2004 Jun 4;279(23):24343-54 – reference: 19326964 - J Neurotrauma. 2009 Aug;26(8):1197-202 – reference: 9855500 - Neurology. 1998 Dec;51(6):1546-54 – reference: 18568035 - Nat Med. 2008 Aug;14(8):837-42 – reference: 21148344 - Science. 2010 Dec 24;330(6012):1774 – reference: 17245412 - Nat Rev Mol Cell Biol. 2007 Feb;8(2):101-12 – reference: 20523023 - Neurodegener Dis. 2010;7(6):349-64 – reference: 21460841 - Nat Genet. 2011 May;43(5):436-41 – reference: 7596406 - Nature. 1995 Jun 29;375(6534):754-60 – reference: 19752451 - Neurology. 2009 Sep 15;73(11):847-53 – reference: 17268505 - EMBO Rep. 2007 Feb;8(2):141-6 – reference: 20879875 - N Engl J Med. 2010 Sep 30;363(14):1293-6 – reference: 11121879 - Neurosci Lett. 2001 Jan 12;297(2):97-100 – reference: 18650432 - J Biol Chem. 2008 Oct 31;283(44):29627-31 – reference: 19864413 - J Biol Chem. 2009 Dec 25;284(52):36024-33 – reference: 17353377 - Arch Neurol. 2007 Mar;64(3):354-62
SSID	ssj0047005
Score	1.9908979
Snippet	Background Aggregatable amyloid β-peptide (Aβ) and non-aggregatable p3-Alcα are metabolic products of the γ-secretase cleavage of amyloid β-protein precursor... Aggregatable amyloid β-peptide (Aβ) and non-aggregatable p3-Alcα are metabolic products of the γ-secretase cleavage of amyloid β-protein precursor (APP) and... BACKGROUND: Aggregatable amyloid β-peptide (Aβ) and non-aggregatable p3-Alcα are metabolic products of the γ-secretase cleavage of amyloid β-protein precursor... Abstract Background Aggregatable amyloid β-peptide (Aβ) and non-aggregatable p3-Alcα are metabolic products of the γ-secretase cleavage of amyloid β-protein...
SourceID	doaj pubmedcentral biomedcentral proquest pubmed crossref springer
SourceType	Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher
StartPage	76
SubjectTerms	Aged Aged, 80 and over Alzheimer Disease - blood Amyloid beta-Peptides - blood Amyloid beta-Protein Precursor - metabolism Amyloid Precursor Protein Secretases - metabolism Animals Asian Continental Ancestry Group Biomedical and Life Sciences Biomedicine Cohort Studies Enzyme-Linked Immunosorbent Assay - methods Female Frontotemporal Lobar Degeneration - blood Humans Male Middle Aged Molecular Medicine Neurology Neurosciences Plasma - metabolism Research Article
SummonAdditionalLinks	– databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LbxMxELZQT1wQUB7hpTkgysWqsw8_egtVq1IBF6jUm-WnGinZpN3kAP8KceYv9Dcx9m4illJx4Rh7FO-sZ2e-scefCXktS2lVEceY5KQjOZVkVFkvqPOKBSaDKnK1-8dP_OSsOj2vz3-76ivVhHX0wN2L2-dRShPr2nhE7iE6VUWhENYXQXpe28xeyhTbJFOdD64Ey8WLGBsZxXyL93SNY8n3t22U08Q0MjjnPhuEp8zi_zfoebOC8o9t1Bydju-Tez2shEmnzgNyJzQPye6kwZR6_hXeQC70zCvou-Tn4QIzzin2BQ_TJsHGNsAiwvUP2iYUuUq_sTUfeYBlxwnboiggWoQl4u25SfItagQxzDHGwCkG3XSZJaQ02fipg8ns20WYzsPVXgv9NhD0LK7tAVyuTZPPt6G3BdMzo6Q_XZZ0MnPX3yGtEIMBhP1w9OH95wl0pNOPyNnx0ZfDE9rf4kAtJisrKlQtgleeF04EK6R1Qtg6FoJJa6yJykdpfKy9YTjVmD05I4M0EqGFLXjg5WOy0yya8JSAKKuA_sPVpYlVHWqjhEP_UUrnfeEKNiIHg8nUy46xQycO7WEPfs46WYJOlqC5FnxE6Gbmtev50dM1HTOd8yTJb8jvbeU349wm-S4Z0uBpcgPaue7tXP_LzkcENmao0QOkbR2c1sW61WosWVmVDNV_0lnldqQikfMjYhsRMbDXwaMMe5rpRSYZR6AtZI3Dvt1Ytu69W3uLms_-h5rPyd28ap8X7l-QndXVOrxE2Leyr_IX_gvsZ1kK priority: 102 providerName: Directory of Open Access Journals – databaseName: Springer Nature OA Free Journals (Selected full-text) dbid: C6C link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1LbxMxELagXLggoDzCS3NAlIvFZnf96i1ErUoFXKBSb5afaqRkE7rJAf5V1TN_ob-JsbOp2IZKHLOejdfyeOYbj-czIW9lJa0q4xCDnFSSU8uCKusFdV4VoZBBlfm0-5ev_OikPj5lp90B2VQL83f-fij5B_RuBcWIiVNOBb9L7rFhxXNSlo83FrcWqEodIeP2Ozcq2ac9B5R5-v8FLrfPSN5IlGb_c_iQPOiAI4zWM_2I3AnNY7I7ajBonv2Ed5CPcuY98l3yezzHmHKCbcHDpEnAsA0wj3B1SduEE5fpNz7NRQ2wWLO-tigKiAdhgYh6ZpJ8iyOCGGboReAY3Wq6rhJSIGz8xMFo-ussTGbhfK-FLtEDHU9ruw8_VqbJFWxoT8F03CfpTxcVHU3d1QWkPWAwgMAeDj5_-jaCNa30E3JyePB9fES7exqoxXBkSYViInjleelEsEJaJ4RlsRSFtMaaqHyUxkfmTRFlio-ckUEaieDBljzw6inZaeZNeE5AVHVAC-FYZWLNAjNKOLQQlXTel64sBmS_N5l6sebk0Iklu9-CC1YnTdBJEzTXgg8I3cy8dh0DerqIY6pzJCT5lvzetfymn9skPyZF6n1NfoCqrDsToDkO3kTGjMcYNESn6igUBqhlkJ4zywYENmqocY2nxA1O63zVajWURVVXBQ7_2Vorr3sqE_0-YrIBET197X1Kv6WZnGUacYTSQjLs9v1Gs3Vnv9pbhvni_0Vfkvt59z1vwL8iO8vzVXiN8G1p3-S1-wfVcEUz priority: 102 providerName: Springer Nature
Title	Coordinated increase of γ-secretase reaction products in the plasma of some female Japanese sporadic Alzheimer's disease patients: quantitative analysis of p3-Alcα with a new ELISA system
URI	https://link.springer.com/article/10.1186/1750-1326-6-76 https://www.ncbi.nlm.nih.gov/pubmed/22067061 https://www.proquest.com/docview/918034300 http://dx.doi.org/10.1186/1750-1326-6-76 https://pubmed.ncbi.nlm.nih.gov/PMC3247855 https://doaj.org/article/6f88af55ad114efc94f791492e8d65b5
Volume	6
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
link	http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LbxMxELZoe-GCgPIIj2gOiHJZ2O6uH1sJoW2UqkS0QpRIuVnetd1GSjZpNpEo_wpx5i_0NzF2NkHbtDdOUexJvF6PZ-azx58JeSNikaeR3UeQ447kJCIM0lzzoNBpaEJh0shnu5-csuN-0hvQwb_8p_oFVrdCO3efVH82ev_j8uoTTviPfsIL9gE9YBggqmIBCzjbIjvolZgDYifJekch4aFPZ1zL1gSOm7-_cfJ91HBYntf_tmB0M6fyxsaq91dHD8mDOtCEbKkZj8g9Uz4mu1mJIHt8BW_Bp376NfVd8qczQQw6xDqjYVi6QLIyMLFw_TuoXFw5d9-x1B-CgOmSJbZCUcD4EaYYgY-Vk6-wR2DNGL0O9NANu-stwb1dpYcFZKOfF2Y4NrO9CuqNIah5XasDuFyo0p94Q_sLquZKcX86jYNsVFz_ArdmDAoQCED3y-ezDJY01E9I_6j7vXMc1Pc6BDnCl3nAU8qNTjWLCm5yLvKC85zaiIciV7myqbZCaUu1Cq1weKpQwgglcFjziBkWPyXb5aQ0zwnwODFoUQoaK5tQQ1XKC7QosSi0jooobJGDxmDK6ZLDQzpW7WYNTnDpNEE6TZBMctYiwWrkZVEzpruLO0bSIyfBNuT31vKrdu6SPHSK1HgaXzCZncvaZEiGnVeWUqURsxpbpInlKQLayAjNaE5bBFZqKNEmuI0eHNbJopLpvgjjJA6x-8-WWrluKXJ0_RjDtQhv6GvjUZo15fDC045j6M0FxWbfrTRbrqbrHd188T-6-ZLc9-v4fin_FdmezxbmNQaC87xNtviAt8lOlvXOevh52D39-g1LO6zT9osrbW8D_gLaf2Vt
linkProvider	Scholars Portal
linkToHtml	http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3JbtswECVS59Beirbp4q5zKJpehCqSuCg3NUjguE4uSYDcCIpLYsCWXcs-tH9V9NxfyDd1SEsBFDdAjxZHpggOh--RnEdCPopUlHni9pDk-JScTMRRXhoeaZPHNhY2T8Jp95NTNrjIhpf0covEbS5MOO3ebkmGSB2GtWBfcJ6LI-ROLGIRZw_ItkAkkvXIdlEMz4Zt9M04ulUjzrj51p2s9klnMgqa_f8CmpvnJe9smoa56OgJedyASCjWvf6UbNnqGdkpKiTQ0x_wCcKxzrBevkP-HMyQX46xzBoYVx4k1hZmDm5-R7XHjEv_G5-GBAeYrxVgazQFxIYwR3Q9Vd6-xhaBs1OcUWCIU6y_uhI8KVZmrKGY_Ly246ld7NbQbPpAo9la78P3lapCNhvGVlCNDor_03kaFRN98wv8ejAoQJAPh6PjswLWEtPPycXR4fnBIGrubIhKpCbLiOeUW5MblmhuSy5KzXlJXcJjUapSudw4oYyjRsVOeK6klbBCCQQSZcIsS1-QXjWr7CsCPM0sRgtNU-UyaqnKucZokQptTKKTuE_2O50p52t9DukVs7sl6EfSe4L0niCZ5KxPorbnpW7U0P2lHBMZWJFgG_a7t_ZtPfdZfvWO1Pma8GC2uJJNOJAMG68cpcogH7VO55njOZLVxArDaEn7BFo3lDje_SYOdutsVct8T8RplsbY_Jdrr7ytKfFS_IjP-oR3_LXzKd2SanwdJMURVnNBsdrPrWfLJpbV9zTz9f-bfiAPB-cnIzk6Pv32hjwKq_JhYf4t6S0XK_sOYd2yfN-M5L9w2U2R
linkToPdf	http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwELZKkRAXBBTo8pwDolyipkn8SMVlWbpqS6mQoFJvluMHXWk3Gza7B_hXiDN_ob-JsZNUSpdKHDeerGN5PPONx_OZkNciFUWeuD0McnxJTibiKC8Mj7TJYxsLmyfhtPunU3Z4lh2f0_MN8q6rhQmn3buUZFPT4FmayuVuZVyzxAXbRZ8XRxhHsYhFnN0itzPv9nyqlo06O5xxVLCWpnH9nWv17dOeWwrs_f-CnOsnJ6-lT4NXGt8n91o4CcNm_h-QDVs-JFvDEkPp2Q94A-GAZ9g53yJ_RnOMNCfYZg1MSg8XawtzB5e_o9qjx6X_jU9DqQNUDRdsjaKAKBEqxNkz5eVrHBE4O0PfAsfobP0lluDDY2UmGobTnxd2MrOLnRra9A-07K31PnxfqTLUtaGVBdUyovg_rdJoONWXv8DvDIMChPtwcHL0ZQgN2fQjcjY--Do6jNrbG6ICg5RlxHPKrckNSzS3BReF5rygLuGxKFShXG6cUMZRo2InfNSklbBCCYQURcIsSx-TzXJe2m0CPM0s2g1NU-UyaqnKuUa7kQptTKKTeED2e5Mpq4apQ3ru7H4LapT0miC9JkgmORuQqJt5qVtedH89x1SG-EiwNfmdK_mun5sk33tF6n1NeDBffJOtYZAMB68cpcpgZGqdzjPHcwxbEysMowUdEOjUUOLK9-kcnNb5qpb5nojTLI1x-E8arbzqKfGk_IjUBoT39LX3Kf2WcnIRyMURYHNBsdu3nWbL1qrVNwzz6f-LviJ3Pn8Yy5Oj04_PyN2wPR926J-TzeViZV8gvlsWL8My_gu9cFBn
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Coordinated+increase+of+%CE%B3-secretase+reaction+products+in+the+plasma+of+some+female+Japanese+sporadic+Alzheimer%27s+disease+patients%3A+quantitative+analysis+of+p3-Alc%CE%B1+with+a+new+ELISA+system&rft.jtitle=Molecular+neurodegeneration&rft.au=Konno+Tomoko&rft.au=Hata+Saori&rft.au=Hamada+Yukiko&rft.au=Horikoshi-Sakuraba+Yuko&rft.date=2011-11-08&rft.pub=BMC&rft.issn=1750-1326&rft.eissn=1750-1326&rft.volume=6&rft.issue=1&rft.spage=76&rft_id=info:doi/10.1186%2F1750-1326-6-76&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_6f88af55ad114efc94f791492e8d65b5
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1750-1326&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1750-1326&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1750-1326&client=summon